Onyx Pharmaceuticals Inc (ONXX.OQ)
131.33USD
1 Jul 2013
$44.51 (+51.27%)
$86.82
$132.63
$132.98
$129.47
3,608,793
399,554
$132.98
$63.52
ONXX.OQ
About
Overall
| Beta: | 1.20 |
| Market Cap (Mil.): | $6,315.14 |
| Shares Outstanding (Mil.): | 72.74 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ONXX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 34.05 | 33.02 |
| EPS (TTM): | -2.51 | -- | -- |
| ROI: | -11.63 | -2.50 | 19.07 |
| ROE: | -17.03 | -3.10 | 20.00 |
Pfizer, Novartis may join Amgen in bidding for Onyx: sources
NEW YORK - Onyx Pharmaceuticals Inc , whose cancer drugs promise a strong revenue stream, is attracting preliminary buyout interest from several large pharmaceutical companies such as Pfizer Inc and Novartis AG , two people familiar with the matter said on Monday.
Onyx explores possible sale after rejecting Amgen offer
NEW YORK - Cancer drugmaker Onyx Pharmaceuticals Inc said on Sunday it rejected a roughly $10 billion takeover offer from larger biotechnology company Amgen Inc as too low but still is considering selling itself.
UPDATE 4-Onyx explores possible sale after rejecting Amgen offer
NEW YORK, June 30 - Cancer drugmaker Onyx Pharmaceuticals Inc said on Sunday it rejected a roughly $10 billion takeover offer from larger biotechnology company Amgen Inc as too low but still is considering selling itself.
Onyx explores possible sale, rejects Amgen offer
NEW YORK - Onyx Pharmaceuticals Inc said on Sunday it rejected a roughly $10 billion takeover offer from larger rival Amgen Inc as too low but is still considering a sale of the company.
UPDATE 3-Onyx explores possible sale, rejects Amgen offer
NEW YORK, June 30 - Onyx Pharmaceuticals Inc said on Sunday it rejected a roughly $10 billion takeover offer from larger rival Amgen Inc as too low but is still considering a sale of the company.
U.S. biotech Amgen offered to buy Onyx for $120 per share: report
- Amgen Inc , the world's largest biotech company, has offered to buy biotech Onyx Pharmaceuticals for $120 per share in cash, Canadian newspaper Financial Post reported on Friday, sending Onyx shares up about 30 percent in after-hours trading.
UPDATE 1-U.S. biotech Amgen offered to buy Onyx for $120 per share -report
June 28 - Amgen Inc, the world's largest biotech company, has offered to buy biotech Onyx Pharmaceuticals for $120 per share in cash, Canadian newspaper Financial Post reported on Friday, sending Onyx shares up about 30 percent in after-hours trading.
U.S. biotech Amgen offered to buy Onyx for $120 per share -report
June 28 - Biotech Amgen Inc has offered to buy smaller biotech Onyx Pharmaceuticals for $120 per share in cash, Canadian newspaper Financial Post reported on Friday, sending Onyx shares up about 30 percent in after-hours trading.
FUNDVIEW-Healthcare M&A to gain pace in 2013 - OrbiMed's Isaly
Feb 7 - Healthcare deals will rebound this year after a weak 2012, with providers of innovative technologies, cancer treatments and diagnostics being the most likely targets, the founder and managing partner of healthcare-focused OrbiMed Advisors said.
Onyx to test cancer drug for wider use
- Onyx Pharmaceuticals Inc said it was planning to test its approved blood cancer drug Kyprolis in patients with newly diagnosed multiple myeloma.
Competitors
| Price | Change | |
|---|---|---|
| Takeda Pharmaceutical Company Limited (4502.T) | ¥4,610 | +50.00 |
| Astellas Pharma Inc (4503.T) | ¥5,490 | +60.00 |
| Pfizer Inc. (PFE.N) | $27.78 | -0.23 |
| Novartis AG (NOVN.VX) | CHF67.30 | +0.20 |
| Merck & Co., Inc. (MRK.N) | $46.32 | -0.13 |
| Roche Holding Ltd. (ROG.VX) | CHF234.60 | -0.40 |
| Bayer AG (BAYGn.DE) | €82.37 | +0.44 |
| Bayer AG (BAYE.F) | -- | -- |
| AstraZeneca plc (AZN.L) | 3,151.00p | +36.00 |
| GlaxoSmithKline plc (GSK.L) | 1,658.50p | +10.50 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
